
Paul Matteis
Stock Analyst at Stifel Nicolaus
(4.60)
# 966
Out of 5,162 analysts
768
Total ratings
46.1%
Success rate
10.3%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTY City Therapeutics | Initiated Coverage: Buy | $34 | $16.64 | +104.33% | 1 | Nov 10, 2026 | |
| MTRI Mentari Therapeutics | Initiated Coverage: Buy | $30 | $15.29 | +96.27% | 1 | Nov 10, 2026 | |
| PEPG PepGen | Reiterated: Buy | $12 | $3.83 | +213.32% | 20 | Nov 10, 2026 | |
| ABOS Acumen Pharmaceuticals | Rated: Hold | n/a | $0.1944 | - | 11 | Nov 9, 2026 | |
| NMRA Neumora Therapeutics | Rated: Hold | n/a | $0.3668 | - | 11 | Nov 9, 2026 | |
| VTGN Vistagen Therapeutics | Rated: Hold | n/a | $0.1995 | - | 9 | Nov 9, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $21 | $8.12 | +158.62% | 9 | Nov 4, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $70 → $66 | $61.43 | +7.44% | 48 | Nov 3, 2026 | |
| SPTX Seaport Therapeutics | Reiterated: Buy | $30 | $18.31 | +63.84% | 4 | Nov 3, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Hold | $563 | $536.45 | +4.95% | 45 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $7.52 | +232.45% | 5 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $318 → $225 | $149.40 | +50.60% | 51 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $242 → $286 | $251.41 | +13.76% | 53 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $40.06 | +32.30% | 5 | Oct 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.24 | +203.03% | 14 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $23.14 | +98.79% | 26 | Oct 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $63 | $46.85 | +34.47% | 60 | Oct 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $2.95 | +476.27% | 10 | Oct 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $15.87 | +133.14% | 29 | Sep 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $20.30 | - | 28 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $37.75 | - | 30 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 | $23.40 | +139.32% | 12 | Sep 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 → $67 | $29.12 | +130.08% | 8 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $2.97 | +135.69% | 6 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $33.27 | +29.25% | 1 | Sep 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 | $18.40 | +122.83% | 29 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $38 | $18.25 | +108.22% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $25 | $17.83 | +40.21% | 51 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $86 → $68 | $27.39 | +148.27% | 33 | Aug 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $188 → $215 | $162.86 | +32.02% | 55 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $133 | $119.04 | +11.73% | 12 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $36 | $6.65 | +441.35% | 4 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $25.91 | +27.36% | 10 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.57 | - | 12 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.65 | n/a | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $9.30 | n/a | 11 | Jun 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $2.77 | n/a | 13 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $20 | $77.98 | n/a | 4 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.00001 | n/a | 1 | Aug 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $20 | $0.0001 | n/a | 4 | Mar 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.10 | n/a | 1 | Nov 23, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.05 | n/a | 4 | Jun 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $0.0001 | n/a | 3 | May 19, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $14 → $7 | $0.3093 | n/a | 2 | May 6, 2016 |
City Therapeutics
Nov 10, 2026
Initiated Coverage: Buy
Price Target: $34
Current: $16.64
Upside: +104.33%
Mentari Therapeutics
Nov 10, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $15.29
Upside: +96.27%
PepGen
Nov 10, 2026
Reiterated: Buy
Price Target: $12
Current: $3.83
Upside: +213.32%
Acumen Pharmaceuticals
Nov 9, 2026
Rated: Hold
Price Target: n/a
Current: $0.1944
Upside: -
Neumora Therapeutics
Nov 9, 2026
Rated: Hold
Price Target: n/a
Current: $0.3668
Upside: -
Vistagen Therapeutics
Nov 9, 2026
Rated: Hold
Price Target: n/a
Current: $0.1995
Upside: -
COMPASS Pathways
Nov 4, 2026
Reiterated: Buy
Price Target: $21
Current: $8.12
Upside: +158.62%
BioMarin Pharmaceutical
Nov 3, 2026
Reiterated: Hold
Price Target: $70 → $66
Current: $61.43
Upside: +7.44%
Seaport Therapeutics
Nov 3, 2026
Reiterated: Buy
Price Target: $30
Current: $18.31
Upside: +63.84%
Vertex Pharmaceuticals
Nov 3, 2026
Reiterated: Hold
Price Target: $563
Current: $536.45
Upside: +4.95%
Oct 30, 2026
Reiterated: Buy
Price Target: $25
Current: $7.52
Upside: +232.45%
Oct 29, 2026
Downgraded: Hold
Price Target: $318 → $225
Current: $149.40
Upside: +50.60%
Oct 29, 2026
Reiterated: Buy
Price Target: $242 → $286
Current: $251.41
Upside: +13.76%
Oct 21, 2026
Reiterated: Buy
Price Target: $53
Current: $40.06
Upside: +32.30%
Oct 12, 2026
Reiterated: Buy
Price Target: $28
Current: $9.24
Upside: +203.03%
Oct 8, 2026
Reiterated: Buy
Price Target: $46
Current: $23.14
Upside: +98.79%
Oct 5, 2026
Reiterated: Buy
Price Target: $63
Current: $46.85
Upside: +34.47%
Oct 5, 2026
Reiterated: Buy
Price Target: $17
Current: $2.95
Upside: +476.27%
Sep 30, 2026
Reiterated: Buy
Price Target: $37
Current: $15.87
Upside: +133.14%
Sep 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $20.30
Upside: -
Sep 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $37.75
Upside: -
Sep 16, 2026
Reiterated: Buy
Price Target: $56
Current: $23.40
Upside: +139.32%
Sep 15, 2026
Reiterated: Buy
Price Target: $60 → $67
Current: $29.12
Upside: +130.08%
Sep 15, 2026
Reiterated: Hold
Price Target: $7
Current: $2.97
Upside: +135.69%
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $33.27
Upside: +29.25%
Aug 7, 2026
Reiterated: Buy
Price Target: $41
Current: $18.40
Upside: +122.83%
Aug 6, 2026
Reiterated: Buy
Price Target: $32 → $38
Current: $18.25
Upside: +108.22%
Aug 5, 2026
Reiterated: Hold
Price Target: $25
Current: $17.83
Upside: +40.21%
Aug 2, 2026
Reiterated: Hold
Price Target: $86 → $68
Current: $27.39
Upside: +148.27%
Jul 31, 2026
Reiterated: Buy
Price Target: $188 → $215
Current: $162.86
Upside: +32.02%
Jun 15, 2026
Reiterated: Buy
Price Target: $133
Current: $119.04
Upside: +11.73%
Jun 2, 2026
Reiterated: Buy
Price Target: $28 → $36
Current: $6.65
Upside: +441.35%
Apr 2, 2026
Reiterated: Buy
Price Target: $33
Current: $25.91
Upside: +27.36%
Dec 22, 2025
Rated: Hold
Price Target: n/a
Current: $2.57
Upside: -
Sep 19, 2024
Rated: Hold
Price Target: n/a
Current: $2.65
Upside: n/a
Jun 3, 2023
Reiterated: Buy
Price Target: $5
Current: $9.30
Upside: n/a
May 12, 2022
Reiterated: Hold
Price Target: $3
Current: $2.77
Upside: n/a
Feb 28, 2022
Downgraded: Hold
Price Target: $11 → $20
Current: $77.98
Upside: n/a
Aug 16, 2017
Initiated Coverage: Buy
Price Target: $18
Current: $0.00001
Upside: n/a
Mar 10, 2017
Reiterated: Buy
Price Target: $14 → $20
Current: $0.0001
Upside: n/a
Nov 23, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.10
Upside: n/a
Jun 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $1.05
Upside: n/a
May 19, 2016
Reiterated: Buy
Price Target: $11
Current: $0.0001
Upside: n/a
May 6, 2016
Reiterated: Hold
Price Target: $14 → $7
Current: $0.3093
Upside: n/a